Recommended Topic Related To:

Follistim AQ Cartridge

"High cholesterol levels may impair fertility in couples trying to achieve a pregnancy, according to a study by researchers at the National Institutes of Health, the University at Buffalo (New York), and Emory University in Atlanta.

Coup"...

Follistim AQ Cartridge

SIDE EFFECTS

The following serious adverse reactions are discussed elsewhere in the labeling:

Clinical Study Experience

Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.

Ovulation Induction

In a single cycle, multi-center, assessor-blind, parallel group, comparative study, a total of 172 chronic anovulatory women who had failed to ovulate and/or conceive with clomiphene citrate therapy, were randomized and treated with Follistim (105) or a urofollitropin comparator. Adverse reactions with an incidence of greater than 2% in either treatment group are listed in Table 2.

Table 2: Common Adverse Reactions Reported at a Frequency of ≥ 2% in an Assessor-Blind, Comparative Study of Anovulatory Women Receiving Ovulation Induction

System Organ Class/
Adverse Reactions
Treatment Number (%) of Women
Follistim
N=105
n (%)
Comparator
N=67
n (%)
Gastrointestinal disorders
  Abdominal discomfort 3 (2.9) 1 (1.5)
  Abdominal pain 3 (2.9) 2 (3.0)
  Abdominal pain lower 3 (2.9) 1 (1.5)
Reproductive system and breast disorders
  Ovarian cyst 3 (2.9) 2 (3.0)
  Ovarian hyperstimulation syndrome 8 (7.6) 3 (4.5)
General disorders and administration site conditions
  Pyrexia 0 (0.0) 2 (3.0)

Adverse reactions reported commonly (greater than or equal to 2% of women treated with Follistim) in other ovulation induction clinical trials were headache, abdominal distension, constipation, diarrhea, nausea, pelvic pain, uterine enlargement, vaginal hemorrhage and injection site reaction.

In Vitro Fertilization/Intracytoplasmic Sperm Injection

In a single cycle, multi-center, double-blind, parallel group, comparative study, a total of 1509 women were randomized to receive controlled ovarian stimulation with either Follistim AQ Cartridge (751 women were treated with Follistim AQ Cartridge) or a comparator and pituitary suppression with a gonadotropin releasing hormone (GnRH) antagonist as part of an in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycle. Table 3 lists adverse reactions with an incidence of greater than 2% in the group of women treated with Follistim AQ Cartridge.

Table 3: Common Adverse Reactions Reported At a Frequency of ≥ 2% in a Randomized, Double-blind, Active-controlled, Comparative Study of Normal Ovulatory Women Undergoing Controlled Ovarian Stimulation as Part of an In Vitro Fertilization or Intracytoplasmic Sperm Injection Cycle

System Organ Class/
Adverse Reactions
Follistim AQ Cartridge Treatment
N = 751
na (%)
Nervous System disorders
  Headache 55 (7.3%)
Gastrointestinal disorders
  Nausea 29 (3.9%)
Reproductive system and breast disorders
  Ovarian Hyperstimulation Syndrome 48 (6.4%)
  Pelvic discomfort 62 (8.3%)
  Pelvic Pain 41 (5.5%)
General disorders and Administration site conditions
  Fatigue 17 (2.3%)
a n = number of women with the adverse reaction

Induction of Spermatogenesis

In an open-label, non-comparative clinical trial, 49 men with hypogonadotropic hypogonadism were enrolled to received pretreatment with hCG, followed by combination therapy with hCG and Follistim for induction of spermatogenesis. Of the 49 men, 30 received weekly Follistim doses of 450 international units; 24 of these 30 men received a total of 48 weeks of treatment with Follistim. Adverse reactions occurring with an incidence of greater than 2% in the 30 men treated with Follistim are listed in Table 4.

Table 4: Common Adverse Reactions Reported At a Frequency of ≥ 2% in an Open-Label Clinical Trial in Men with Hypogonadotropic Hypogonadism

System Organ Class/
Adverse Reactions
Follistim Treatment
N=30
n (%)
Nervous system disorders
  Headache 2 (6.7)
General disorders and administration site disorders
  Injection site reaction 2 (6.7)
  Injection site pain 2 (6.7)
Skin and cutaneous tissue disorders
  Acne 2 (6.7)
  Rash 1 (3.3)
Reproductive system and breast disorders
  Gynecomastia 1 (3.3)
Neoplasms benign, malignant and unspecified
  Dermoid cyst 1 (3.3)

Postmarketing Experience

The following adverse reactions have been identified during post approval use of Follistim and/or Follistim AQ Cartridge. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Gastrointestinal disorders

Abdominal distension, abdominal pain, constipation, diarrhea

General disorders and administration site conditions

Injection site reaction

Reproductive system and breast disorders

Breast tenderness, metrorrhagia, ovarian enlargement, vaginal hemorrhage

Skin and subcutaneous tissue disorders

Rash

Vascular disorders

Thromboembolism [see WARNINGS AND PRECAUTIONS]

Read the Follistim AQ Cartridge (follitropin beta injection) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

No drug-drug interaction studies have been performed.

Last reviewed on RxList: 9/6/2011
This monograph has been modified to include the generic and brand name in many instances.

A A A

Follistim AQ - User Reviews

Follistim AQ User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Follistim AQ sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Trying to Conceive

Get tips and advances in treatment.